Sanofi
NASDAQ:SNY · NASDAQ Global Select
-$0.31 today
Vol 3.86M · Avg 2.78M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SNY · Revenue to Net Income
Key Ratios
Analysis
$47.4B of revenue converted into $7.6B of net income for the selected period. Gross margin is 72.1% and net margin is 16.4%, showing how much revenue survives after costs and taxes. EPS is $1.95, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $46.7B +5.5% | $44.3B +6.4% | $41.6B +2.6% | $40.6B +3.5% | $39.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $13.0B -1.2% | $13.2B +4.6% | $12.6B +6.3% | $11.9B -3.0% | $12.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $33.7B +8.3% | $31.1B +7.2% | $29.0B +1.1% | $28.7B +6.5% | $26.9B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 72.1% +1.9pp | 70.2% +0.5pp | 69.7% -1.0pp | 70.7% +2.0pp | 68.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $7.8B +6.1% | $7.4B +13.6% | $6.5B +0.1% | $6.5B +14.2% | $5.7B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $10.2B +11.5% | $9.2B +2.8% | $8.9B +2.2% | $8.7B -8.5% | $9.6B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $24.1B +1.0% | $23.8B +8.2% | $22.0B +19.0% | $18.5B -1.5% | $18.8B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.7B +58.3% | $3.6B -19.0% | $4.4B +42.5% | $3.1B -7.3% | $3.4B | $374.2M | $1.2B | $631.8M |
| EBITDA | $12.5B +13.1% | $11.0B -3.1% | $11.4B -15.7% | $13.5B +17.1% | $11.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 26.7% +1.8pp | 24.9% -2.5pp | 27.4% -5.9pp | 33.3% +3.9pp | 29.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $9.6B +32.3% | $7.3B +4.2% | $7.0B -31.5% | $10.2B +25.1% | $8.1B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 20.5% +4.2pp | 16.4% -0.3pp | 16.7% -8.3pp | 25.1% +4.3pp | 20.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $331.0M -27.7% | $457.5M -13.8% | $530.5M +214.0% | $169.0M +5303.2% | $3.1M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $626.0M +0.6% | $622.6M +21.4% | $512.8M +33.3% | $384.8M +2.0% | $377.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$3.6B -624.1% | -$494.0M +41.5% | -$845.0M -397.1% | -$170.0M +41.2% | -$289.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $6.0B -10.9% | $6.8B +10.5% | $6.1B -38.8% | $10.0B +27.5% | $7.8B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 12.9% -2.4pp | 15.3% +0.6pp | 14.7% -9.9pp | 24.6% +4.6pp | 20.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.0B -13.4% | $1.2B +18.4% | $1.0B -46.7% | $1.9B +22.5% | $1.6B | $1.3B | -$1.6B | $745.2M |
| Net Income | $7.8B +40.5% | $5.6B +3.0% | $5.4B -35.5% | $8.4B +34.5% | $6.2B | $4.9B | $4.8B | $4.7B |
| Net Margin | 16.7% +4.2pp | 12.6% -0.4pp | 13.0% -7.7pp | 20.6% +4.8pp | 15.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +46.1% | $2 +1.9% | $2 -32.6% | $3 +28.1% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +46.1% | $2 +1.9% | $2 -32.4% | $3 +27.7% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $2.4B -2.5% | $2.5B -0.0% | $2.5B -0.0% | $2.5B -0.0% | $2.5B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $2.4B -2.5% | $2.5B -0.4% | $2.5B +0.4% | $2.5B -0.0% | $2.5B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$180.74B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.43B
Pfizer Inc.
NYSE:PFE
$143.77B
CVS Health Corporation
NYSE:CVS
$125.44B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$114.73B
Bristol-Myers Squibb Company
NYSE:BMY
$109.97B
GSK plc
NYSE:GSK
$101.86B
Medtronic plc
NYSE:MDT
$101.25B
HCA Healthcare, Inc.
NYSE:HCA
$83.31B
Bristol-Myers Squibb Company Ce
CELG-RI
$245.05M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SNY generate?
Sanofi (SNY) reported $46.72B of revenue in fiscal 2025.
Is SNY profitable?
Sanofi (SNY) reported $7.81B of net income, with a net margin of 16.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.